title: [Practice of antihypertensive treatment in diabetic patients with hypertension in Hungary].
abstract: Diabetes mellitus as comorbidity is present in 20-25% of patients suffering from high blood pressure. Because simultaneous presence of these two diseases results in a significant increase of cardiovascular risk, various guidelines chiefly focus on the antihypertensive treatment of patients with diabetes. Combined drug therapy is usually required to achieve the blood pressure target value of <140/85 mmHg defined for patients with diabetes, which must be based on angiotensin converting enzyme-inhibitors or angiotensin receptor blockers. These can be/must be combined with low dose, primarily thiazide-like diuretics, calcium channel blockers with neutral metabolic effect, and further options include the addition of beta blockers, imidazoline-l-receptor antagonists, or alpha-1-adrenoreceptor blockers. Evidence-based guidelines are obviously present in local practice. Although most of the patients receive angiotensin converting enzyme-inhibitor+indapamide or angiotensin converting enzyme-inhibitor+calcium channel blocker combined therapy with favorable metabolic effects, yet the use of angiotensin converting enzyme-inhibitors containing hydrochlorothiazide having diabetogenic potential, and angiotensin receptor blocker fixed combinations is still widespread. Similarly, interesting therapeutic practice can be observed with the use of less differentiated beta blockers, where the 3rd generation carvedilol and nebivolol are still in minority.
authors.affiliation: Petz Aladár Megyei Oktató Kórház Kardiológiai Osztály Győr Vasvári Pál u. 2-4. 9024.
authors.forename: Veronika
authors.initials: V
authors.lastname: Szentes
authors.affiliation: Petz Aladár Megyei Oktató Kórház Kardiológiai Osztály Győr Vasvári Pál u. 2-4. 9024.
authors.forename: Gabriella
authors.initials: G
authors.lastname: Kovács
authors.affiliation: Petz Aladár Megyei Oktató Kórház Kardiológiai Osztály Győr Vasvári Pál u. 2-4. 9024.
authors.forename: Csaba András
authors.initials: CA
authors.lastname: Dézsi
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001795:Blood Pressure Determination; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D048909:Diabetes Complications / Q000188:drug therapy*; D004232:Diuretics / Q000627:therapeutic use; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D004359:Drug Therapy, Combination; D006801:Humans; D006814:Hungary; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D054755:Imidazoline Receptors / Q000037:antagonists & inhibitors; D007388:Internal Medicine / Q000706:statistics & numerical data; D010821:Physicians, Family / Q000706:statistics & numerical data; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011412:Propanolamines / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002227:Carbazoles; D004232:Diuretics; D054755:Imidazoline Receptors; D011412:Propanolamines; C410887:imidazoline I1 receptors; D006852:Hydrochlorothiazide; D000077261:Carvedilol
keywords: diabetes mellitus; guidelines; hypertension; hypertonia; szakmai ajánlások; terápiás gyakorlat; therapy in practice